Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 14, 2024 (2 years ago)

Klarity-C (cyclosporine)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Klarity-C (cyclosporine) Preservative-Free Sterile Ophthalmic Emulsion 0.1% 5.5mL, Rx Only, This is a compounded drug. NOT FOR RESALE. OFFICE USE ONLY Compounded by: Imprimis NJOF, LLC., 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852 NDC: 71384-514-05

Affected NDC 71384-0514-05

Compare with the code on your package — it is the most precise check available.

Drug: Cyclosporine Category: Eye Drops & Ophthalmic

Recalling firm
Imprimis NJOF, LLC
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0547-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Cyclosporine recalls

See all
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Ongoing Failed specification Novartis Pharmaceuticals Corporation NDC 0078-0110-22 D-0144-2024
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

Ongoing Failed specification Novartis Pharmaceuticals Corp. NDC 0078-0110-22 D-1174-2023
Class II · Moderate risk

Cyclosporine

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0200-2023

Other recalls by Imprimis NJOF, LLC

All 2024 recalls